AstraZeneca buys rights to anaemia drug from FibroGen
LONDON (Reuters) - AstraZeneca took a further step to bolster its new drug pipeline on Wednesday by striking a deal with private biotech firm FibroGen potentially worth more than $815 million for rights to an experimental anaemia drug.
Britain's second biggest drugmaker will pay $350 million upfront and in subsequent non-contingent payments, plus future development-related milestone payments of up to $465 million, for rights to FG-4592 in the United States, China and certain other markets.
There may be additional payments if use of the drug is expanded.
Japan's Astellas Pharma already has rights to the medicine in Japan, Europe, the Commonwealth of Independent States, the Middle East and South Africa.
- Exclusive: Malaysia plane probe narrows on mid-air disintegration - source
- Radar showed missing plane may have turned back: Malaysia military
- Missing Malaysian jet may have disintegrated in mid-air: source |
- Malaysian plane presumed crashed; questions over false IDs |
- Merkel raps Putin as Russian forces tighten grip on Crimea |